Abstract 452P
Background
Cancer is the leading cause of death worldwide. In 2012, around 8,2 million deaths were caused by cancer.1 Chemotherapy in cancer patients is often accompanied by bone marrow aplasia which manifests as anemia. The choice of therapy for anemia in cancer patients are blood transfusions. In addition, an Erythropoiesis-Stimulating Agent (ESA) can be added which can increase the production of erythrocytes in the bone marrow.17,18 Increased erythropoeisis process induced by ESA will bind to Erythropoietin Receptor (EpoR) on the erythropoetic cell surface in the bone marrow. In other hand, ESA therapy were still not giving a satisfied result and still lack of data about expression of EpoR. Absolute reticulocyte count (ARC) is a marker of erythrocyte production that is more accurate in distinguishing hypo or hyperproliferative anemia.
Methods
This study was an observational analytic, cross sectional study carried out at the hematology specialty clinic, integrated oncology unit, Department of Internal Medicine, Dr. M. Djamil Padang Hospital for 6 months. A sample of 30 patients who met the inclusion and exclusion criteria. Initial screening for potential subjects was carried out, the research protocol was explained and informed consent was requested.
Results
There is a decrease of EpoR expression (8481,33±5364,46 copies/uL) compared to normal value (34-3000 x 103 copies/uL). There is also a decrease of ARC (27,97±9,24 x109/L) compared to normal value (50-100 x109/L). Positive correlation was found between EpoR expression and ARC. In the statistical test using the Pearson test it was found that the correlation was significant (p < 0.05) with very strong gradations (r = 0.819).
Conclusions
There is a decrease the average of EpoR expression in patient with anemia related chemotherapy and significant positive correlation with a very strong gradation between EpoR expression and ACR .
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Division of Hematology and Medical Oncology, Internal Medicine Department, Dr. M. Djamil General Hospital, Padang, Indonesia.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
9P - XRCC1 Arg194Trp, Palb2 T1100T (3300T>G), HMMR V353A, TNF aG308A polymorphisms as diagnostic and prognostic markers of breast cancer in the Kyrgyz ethnic group
Presenter: Aigul Semetei kyzy
Session: Poster display session
Resources:
Abstract
232P - Early Results from the Phase I Study of SY-1365, a Potent and Selective CDK7 inhibitor, in Patients with Ovarian Cancer and Advanced Solid Tumors
Presenter: Debra Richardson
Session: Poster display session
Resources:
Abstract
382P - Drug metabolizing enzymes pharmacogenomic: Biomarkers for improved chemotherapy in head and neck cancer squamous cell carcinoma
Presenter: Sunishtha Bhatia
Session: Poster display session
Resources:
Abstract
401P - Women in oncology: Alarming figures from India
Presenter: Sharada Mailankody
Session: Poster display session
Resources:
Abstract
416P - Multidisciplinary management of sarcomas of the head and neck: An institutional experience
Presenter: Kavitha Jain
Session: Poster display session
Resources:
Abstract
523P - Co-morbilities and survival of patients initially diagnosed with extensive-stage small cell lung cancer: Impact of hypertension, diabetes and chronic hepatitis B viral infection
Presenter: Weigang Xiu
Session: Poster display session
Resources:
Abstract
529P - Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Presenter: Roni Gillis
Session: Poster display session
Resources:
Abstract